A multidimensional workflow profiling of allogeneic virus-specific T cell therapies reveals potency-linked signatures

Corey Smith(QIMR Berghofer Medical Research Institute), Rajiv Khanna(The University of Queensland), George Ambalathingal(The University of Queensland), Sweera Rehan(QIMR Berghofer Medical Research Institute), Sriganesh Srihari(QIMR Berghofer Medical Research Institute), Arushi Mahajan(QIMR Berghofer Medical Research Institute), Matthew D. Solomon(Sutter Health), Leone Beagley, Vijayendra Dasari(QIMR Berghofer Medical Research Institute), Archana Panikkar(QIMR Berghofer Medical Research Institute), Panteha Khaledi(QIMR Berghofer Medical Research Institute), Laëtitia Le Texier(QIMR Berghofer Medical Research Institute), Jyothy Raju(QIMR Berghofer Medical Research Institute), Thuy Le(QIMR Berghofer Medical Research Institute), Pamela Mukhopadhyay(QIMR Berghofer Medical Research Institute), Pauline Crooks(QIMR Berghofer Medical Research Institute)
Nature Communications
January 6, 2026
10.1038/s41467-025-67924-w
Cited by 1

Related Papers

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity
|Cancer Discovery|2019|272
Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.
|Journal of Clinical Pathology|1984|261
Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen–specific CD8+ T-cell function in Hodgkin lymphoma patients
|Blood|2006|250
A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses
|Proceedings of the National Academy of Sciences|2004|235
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies
|Clinical Microbiology Reviews|2017|226